SYSTEMATIC REVIEW

Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis

Filippo Migliorini^{1*}, Nicola Maffulli^{2,3,4}, Giorgia Colarossi¹, Jörg Eschweiler¹, Markus Tingart¹ and Marcel Betsch⁵

Abstract

Background: Osteoporosis affects mostly postmenopausal women, leading to deterioration of the microarchitectural bone structure and low bone mass, with an increased fracture risk with associated disability, morbidity and mortality. This Bayesian network meta-analysis compared the effects of current anti-osteoporosis drugs on bone mineral density.

Methods: The present systematic review and network meta-analysis follows the PRISMA extension statement to report systematic reviews incorporating network meta-analyses of health care interventions. The literature search was performed in June 2021. All randomised clinical trials that have investigated the effects of two or more drug treatments on BMD for postmenopausal osteoporosis were accessed. The network comparisons were performed through the STATA Software/MP routine for Bayesian hierarchical random-effects model analysis. The inverse variance method with standardised mean difference (SMD) was used for analysis.

Results: Data from 64 RCTs involving 82,732 patients were retrieved. The mean follow-up was 29.7 ± 19.6 months. Denosumab resulted in a higher spine BMD (SMD -0.220; SE 3.379), followed by pamidronate (SMD -5.662; SE 2.635) and zoledronate (SMD -10.701; SE 2.871). Denosumab resulted in a higher hip BMD (SMD -0.256; SE 3.184), followed by alendronate (SMD -17.032; SE 3.191) and ibandronate (SMD -17.250; SE 2.264). Denosumab resulted in a higher femur BMD (SMD 0.097; SE 2.091), followed by alendronate (SMD –16.030; SE 1.702) and ibandronate (SMD -17.000; SE 1.679).


© The Author(s), 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.

Conclusion: Denosumab results in higher spine BMD in selected women with postmenopausal osteoporosis. Denosumab had the highest influence on hip and femur BMD.

data made available in this article, unless otherwise stated in a credit line to the data.

Level of evidence: Level I, Bayesian network meta-analysis of RCTs

Keywords: Osteoporosis, Bone mineral density, Drugs, Denosumab





^{*} Correspondence: migliorini.md@gmail.com

¹Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074 Aachen, Germany Full list of author information is available at the end of the article

Page 2 of 15

Introduction

Osteoporosis is common in postmenopausal women, with microarchitectural deterioration and low bone mass. Approximately, 19% of men and 30% of women in Europe and in the USA are at risk for osteoporosis, and annually around 9 million osteoporosis associated fractures occur [1]. Osteoporosis-associated fractures result in increased disability, mortality and health-care costs, and therefore the treatment and prevention of osteoporotic fractures carries significant clinical and public health importance [2].

Current approved pharmacological treatments for postmenopausal osteoporosis can be divided into antiresorptive and anabolic medications [3]. Briefly, antiresorptive drugs reduce bone resorption, whilst anabolic drugs increase bone formation. The most commonly prescribed agents are anti-resorptive drugs, which include bisphosphonates (BP) (e.g. alendronate, risedronate, zoledronic acid, ibandronate, etidronate), selective oestrogen receptor modulators (SERM) (e.g. raloxifene) and the RANK-ligand inhibitor (e.g. denosumab).

BP were discovered during the search for pyrophosphonate analogues, attempting to benefit from the inhibitory effects of pyrophosphates on calcification [4]. BP work by inhibiting the enzyme farnesyl pyrophosphonate synthase in osteoclasts, influencing their affinity for bone mineral uptake [5, 6]. During early treatment, SERMs decrease bone remodelling by about 20-30%, and thereby result in a modest transitory increase in bone mineral density (BMD) [7]. However, during prolonged therapy, SERMs lead to a decline in BMD, which may account for the only modest reduction in vertebral fracture risk [7].

Denosumab is a monoclonal antibody against the receptor activator of nuclear factor-kappa B ligand (RANK-ligand), a regulator of osteoclast development. By blocking the RANK-ligand with denosumab the activity, survival and recruitment of osteoblast are inhibited.

Anabolic osteoporosis drugs, such as teriparatide, are usually reserved for patients with severe and established osteoporosis. Both medications lead to an increase in trabecular thickness and improved trabecular microstructure via the teriparatide (PTHR1) receptor [8, 9]. Finally, romosozunab is a novel sclerostin antibody recently approved for the treatment of osteoporosis. Romosozunab has antifracture and anabolic efficacy, increasing bone formation and decreasing bone resorption [10, 11].

Network analysis may provide clinically relevant evidence in the absence of randomised controlled trials (RCTs) comparing relevant pharmaceutical treatments for osteoporosis. Therefore, we conducted this network meta-analysis comparing the effects of nine osteoporosis drugs and their effects on BMD in patients with post-menopausal osteoporosis.

Methods

Search strategy

The present systematic review and network metaanalysis follows the PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions [12]. The follow algorithm guided the preliminary search:

- P (population): postmenopausal osteoporosis
- I (intervention): medical treatments
- C (comparison): denosumab, raloxifene, teriparatide, alendronate, risedronate, zoledronate, ibandronate, etidronate, strontiumranelate
- O (outcomes): BMD

Data source and extraction

The literature search was performed by two independent authors (FM; GC). In June 2021, the databases search started. The search on PubMed was performed with the following string: osteoporosis [All Fields] AND (bone [All Fields] OR endocrinology [All Fields]) AND (postmenopausal [All Fields] OR treatment [All Fields] OR management [All Fields] OR spine [All Fields] OR femur [All Fields] AND hip [All Fields] OR BMD [All Fields]) AND (mineral density [All Fields] OR Bisphosphonates [All Fields] OR Denosumab [All Fields] OR Raloxifene [All Fields] OR Teriparatide [All Fields] OR Alendronate [All Fields] OR Risedronate [All Fields] OR Zoledronate [All Fields] OR Ibandronate [All Fields] OR Etidronate [All Fields] OR Calcium [All Fields] OR Vitamin D [All Fields] OR PTH [All Fields] OR osteoblast [All Fields] OR osteoclast [All Fields]) AND management [All Fields] OR therapy [All Fields]. The same search strings were used to search Google Scholar, Embase and Scopus. The resulting titles and subsequent abstracts were screened by the same two authors. If they matched the topic, the article full-text was accessed. A cross reference of the bibliographies was also performed. Disagreement was debated and solved by a third senior author (NM).

Eligibility criteria

All the randomised clinical trials (RCTs) investigating the effects of two or more drug treatments on BMD for postmenopausal osteoporosis were accessed. Given the authors language capabilities, articles in English, German, Italian, French and Spanish were eligible. Only levels I and II RCTs according to the Oxford Centre of Evidence-Based Medicine [13] were considered. Only articles reporting quantitative data under the outcomes of interest and articles with a minimum 12 months followup were considered. Studies treating patients with calcium and vitamin D without any other drugs were not included. Studies reporting data on patients with iatrogenic-induced menopause were not included, as well as those treating paediatric and/or adolescent patients. Studies on patients undergoing immunosuppressive therapies or organ transplantation were also not considered. Studies reporting data on patients with malignancies or pathological bone diseases other than osteoporosis were not included. Studies reporting data on mixed treatments or taking advantage from adjuvants were excluded. Editorials, registries, comments, expert opinions and reviews were not eligible. Animals or in vitro studies were also not eligible. Missing data under the outcomes of interest warranted the exclusion from this study.

Outcomes of interest

Two authors (FM; GC) performed data extraction. Study generalities (author, year, journal, duration of the followup) and patient baseline demographic information were collected: number of samples and related mean age, percentage of female, mean bone mass index (BMI) and mean BMD (overall, spine, hip, femur neck). The following drugs were considered in the analyses: denosumab, raloxifene, teriparatide, alendronate, risedronate, zoledronate, ibandronate and etidronate. The outcome of interest was BMD at last follow-up.

Methodology quality assessment

The methodological quality assessment was performed by two authors (FM; GC). The risk of bias summary tool of the Review Manager Software (The Nordic Cochrane Collaboration, Copenhagen) was used for evaluation. The following risk of bias was assessed: selection, detection, attrition and other source of bias.

Statistical analysis

The statistical analyses were performed by the main author (FM). Baseline comparability was assessed through the IBM SPSS software. The analysis of variance (ANOVA) was used for analysis, with P values > 0.1 was considered satisfactory. The STATA Software/MP, Version 14.1 (StataCorporation, College Station, Texas, USA) was used for the statistical analyses. The NMA was performed through the STATA routine for Bayesian hierarchical random-effects model analysis. The placebo treatment was used as reference group. The inverse variance method was used for analysis, with standardised mean difference (STD) and standard error (SE) effect measures. The overall inconsistency was evaluated through the equation for global linearity via the Wald test, with P values< 0.05 indicating statistically significant inconsistency. Otherwise, if P > 0.05 the null hypothesis cannot be rejected, and the consistency assumption could be accepted at the overall level of each treatment. Both confidence (CI) and percentile (PrI) intervals were set at 95%. Edge plot, interval plots and funnel plots were obtained and evaluated.

Results

Search result

The primary literature search resulted in 1354 articles. Of them, 477 were RCTs. A further 101 were removed because duplicated. Additional 270 articles were excluded because of the study design (N = 26), non-clinical studies (N = 34), glucocorticoid-induced osteoporosis (N = 51), treatment of bone malignancies (N = 56), language limitations (N = 12) and others (N = 91). A further 42 articles were excluded because it did not report quantitative data under the outcomes of interests. Finally, 64 RCTs were included for analysis. The literature search results are shown in Fig. 1.

Methodological quality assessment


The risk of bias summary evidenced some point of strength of the present study. First, the randomised design of all the included studies leads to low risk of selection bias. Moreover, most studies performed assessors, patients and personnel blinding, thus leading to a low risk of performance and detection bias. The risk of attrition and reporting bias were both low. The risk to incur in unknown/other bias was low to moderate. Concluding, the risk of bias was low, attesting to the methodological assessment of the present study is a very good quality. The score of each risk of bias item for each included study is shown in Fig. 2.

Patient demographics

Data from 82,732 patients were retrieved. The mean follow-up was 29.7 \pm 19.6 months. The mean age of the patients was 67.3 \pm 6.1 years. The mean BMI was 25.0 \pm 1.7 kg/m². The mean BMD at baseline of the spine was 0.83 \pm 0.11, of the hip was 0.74 \pm 0.07 and of the femoral neck was 0.63 \pm 0.07 g/cm². The ANOVA test found baseline comparability (P > 0.1) with regards to age, BMI and BMD. Studies' generalities and patients' demographics are shown in Table 1.

Outcomes of interest

Denosumab resulted in a higher spine BMD (SMD -0.22; SE 3.38; 95% CI -6.84 to 6.40), followed by pamidronate (SMD -5.66; SE 2.64; 95% CI -10.83 to -0.50) and zoledronate (SMD -10.70; SE 2.87; 95% CI -16.33 to -5.07). Denosumab resulted in a higher hip BMD (SMD -0.26; SE 3.18; 95% CI -6.50 to 5.98), followed by alendronate (SMD -17.03; SE 3.19; 95% CI -23.29 to -10.78) and ibandronate (SMD -17.25; SE 2.26; 95% CI -21.69 to -12.81). Denosumab resulted in a higher



femur BMD (SMD 0.10; SE 2.09; 95% CI –4.00 to 4.20), followed by alendronate (SMD –16.03; SE 1.70; 95% CI –19.37 to –12.69) and ibandronate (SMD –17.00; SE 1.68; 95% CI –20.29 to –13.71). The equation for global linearity found no statistically significant inconsistency (P > 0.05) in all comparisons. Edge, funnel and interval plots of these comparisons are shown in Fig. 3.

Discussion

Over the last decades, effective pharmaceutical treatments have been developed for the management of osteoporosis. However, most studies have not included multiple active comparators because of cost constraints, ethical problems and government regulations. This network meta-analysis is the first to include 64 RCTs with a total of 82,732 patients, including only studies with levels of evidence 1 and 2. This study compared and evaluated the influence of currently available pharmacological treatments for osteoporosis with one another in terms of BMD. The present investigation shows that denosumab was associated with the highest BMD of all evaluated osteoporosis drugs in selected women with postmenopausal osteoporosis.

Meta-analyses are considered valuable tools to analyse different studies. However, they only allow a pair-wise assessment of treatments. In contrast, network metaanalyses allow to blend together information over a network of comparisons to compare the relative effects of different treatments used for the same condition. Network meta-analysis provides vital clinical information by ranking the relative efficacy of all interventions, even those which have not been compared with one another directly.

Most previous network meta-analyses have investigated the effects of osteoporosis treatments on fracture risk, which is in contrast to our analysis which instead

ive in reducing vertebral fractures compared to placebo, and that they are beneficial for change in femoral neck BMD [17]. Romosozunab, followed by alendronate, resulted in the greatest effect on femoral BMD. Previous studies suggest that anabolic osteoporosis treatments, such as abaloparatide and teriparatide, exert the highest influence on reducing the overall fracture risk. The present study shows that denosumab has the greatest effect on BMD, independent of the fracture risk. Denosumab demonstrates a high affinity and specificity to the RANKL, and therefore prevents it from binding to the RANKL receptors on osteoclasts and their precursors, with a direct effect on the activity and life span of existing osteoblasts [18]. Denosumab increases BMD by inhibiting bone resorption and remodelling [19]. The

FREEDOM trial confirmed that denosumab, adminis-

trated every 6 months, significantly reduces the hip frac-

ture risk by 40%, the non-vertebral fracture risk by 20% and the vertebral fracture risk by 68% [20]. The extension of the FREEDOM study showed that treatment with denosumab up to 10 years results in a cumulative gain in BMD of 21.7% at the lumbar spine, and 9.2% at the total hip, compared to baseline [21]. Denosumab resulted in lower rates of new vertebral and non-vertebral fractures throughout the study period [21]. Denosumab is administrated subcutaneously every 6 months, and therefore it is likely that the adherence to the medication is better compared to BP. This was confirmed by Kendler et al., who showed greater satisfaction when patients transitioned to denosumab as compared to a monthly oral BP [22]. Palacios et al. also confirmed a higher adherence of patients to denosumab compared to BP, and that most patients do prefer denosumab over BP for the treatment of osteoporosis [23]. The advantages of denosumab over BP seem the more favourable side-effect profile (low rates of infections and malignancies), and, as shown in the present study, the more



focused on the influence of drugs on BMD. A recent network meta-analysis of 22 RCTs studied the relative efficacy of 10 osteoporosis drugs in postmenopausal women at high risk of fragility fractures [14]. Abaloparatide had the highest probability of preventing vertebral, non-vertebral, and wrist fractures compared to placebo and all other treatment options. This was also confirmed by another network meta-analysis of 67,524 patients: both abaloparatide and teriparatide significantly reduced the fracture risk compared to placebo and other osteo-

porosis medications [15]. In addition, a further network


meta-analysis confirmed that teriparatide seemed to be

most effective in preventing new non-vertebral fractures

in patients with osteoporosis [16]. A systematic review

and network meta-analysis of RCTs evidenced that non-

bisphosphonate interventions (including denosumab, raloxifene, teriparatide, romosozunab) are clinically effect-





nab IM 32 rate IV 26 IV 26 ate IV 26 IV 26 ate IV 3875 ate V 3861 ate OS 3861 ide SC 73 ate OS 333 ate OS 333 ate OS 333 ate OS 333 ate OS 93 ate OS 97 ate OS 97 ate OS 97 ate OS 97 </th <th>Author, year Journal</th> <th>nal</th> <th>Follow-up (<i>months</i>)</th> <th>Calcium daily supplement (<i>mg</i>)</th> <th>Vit D daily supplement (<i>U</i>)</th> <th>Treatment</th> <th>Administration</th> <th>Samples (<i>n</i>)</th> <th>Mean age</th> <th>Mean BMI (<i>kg/m²</i>)</th> <th>BMD Spine (g/cm²)</th> <th>BMD Hip $(g^{\prime})^{2}$</th> <th>BMD Femur neck (<i>g/cm</i>²)</th>	Author, year Journal	nal	Follow-up (<i>months</i>)	Calcium daily supplement (<i>mg</i>)	Vit D daily supplement (<i>U</i>)	Treatment	Administration	Samples (<i>n</i>)	Mean age	Mean BMI (<i>kg/m²</i>)	BMD Spine (g/cm ²)	BMD Hip $(g^{\prime})^{2}$	BMD Femur neck (<i>g/cm</i> ²)
		teoporos Int	12	1000	800	Denosumab	MI	32	63	28.80	0.97		
Media 1 Placebo N 241 $Media 1 1000-1500 400-1500 20edonate N 385 Media 1 1000 400-1200 20edonate N 385 Media 1 1000 400-1200 4endonate 05 365 Media 36 652 Aendonate 05 323 Media 66 55 Aendonate 05 323 Media 66 1000-1500 400-1200 67 323 JBone Min Res 36 1000-1500 20edonate 05 323 JBone Min Res 36 1000-1500 20edonate 05 323 JBone Min Res 13 1000-1500 $	2015 [29]					Zoledronate	\geq	26	63	28.70	0.94		
Wee Figland Med 36 1000-1500 400-1300 Zolestonate N 3875 Jan Endocrinol Med 14 100 400-1300 Zolestonate 1 361 Jan Endocrinol 14 100 400-1300 Alendronate 55 73 Jan Endocrinol 14 100 400-1300 Alendronate 55 73 Jan Line Loncet 36 653 Alendronate 55 1000 Jan Line Loncet 36 653 Alendronate 55 1000 Jane Min Ris 36 1000-1500 400-1200 204edronate 55 333 Jane Min Ris 36 1000-1500 400-1200 204edronate 56 333 Jane Min Ris 36 1000-1500 400-1200 204edronate 56 333 Jane Min Ris 36 1000-1500 204edronate 56 333 Jane Min Ris 36 1000-1500 204edronate 56 56 Jane Min Ris <t< td=""><td></td><td></td><td></td><td></td><td></td><td>Placebo</td><td>\geq</td><td>241</td><td>57</td><td>23.73</td><td>0.92</td><td>0.65</td><td>0.63</td></t<>						Placebo	\geq	241	57	23.73	0.92	0.65	0.63
Med 1 1 3		w England J	36	1000-1500	400-1200	Zoledronate	\geq	3875	73	25.10	0.79	0.65	0.53
JCIn Endocrind Metab 14 100 400-100 Rendonate 05 73 The Lancet 36 632 Teriparatide 5C 73 Metab 619 Americonate 05 1002 102 JMM 60 655 Americonate 05 102 JMM 60 655 Americonate 05 102 JBM 166 400-1500 400-1200 05 33 JBM 35 1000-1500 400-1200 106 33 JBM 166 7 264chonate 05 33 JBM 10 264chonate 05 05 05 JBM 10	30]	Med				Placebo	≥	3861	73	25.40	0.79	0.65	0.53
Metab Teriparatide SC 73 The lancet 36 632 102 102 JMM 60 65 2 102 JMM 60 65 33 1003 JMM 60 65 33 1003 JMM 60 65 34 1003 33 JMM 60 65 467 33 33 JMM 60 65 4001200 4001200 33 33 JBone Min Res 36 10001500 4001200 20 47 41 JBone Min Res 36 10001500 4001200 4001200 1 93 JCIN Endocrinol 24 81 4001200 20 93 93 JCIN Endocrinol 24 81 4001200 40010000 1 93 93 JENDE MIN Res 13 10 10 10 1 1 1 JENDE MIN Res		in Endocrinol	14	1000	400-1200	Alendronate	OS	73	65	24.40	0.80		
The Lancet 36 62 23 102 MM 60 65 $Hendronate$ 05 33 67 $Hendronate$ 05 $Hendronate$ 05 33 1000 100 100 100 100 100 105 1000 100 100 100 100 100 105 105 1000 100 100 100 100 100 105 105 1000 100 100 100 100 100 105 105 1000 100 100 100 100 100 105 1000 100 100 100 100 100 100 <	31]	Metab				Teriparatide	SC	73	99	23.90	0.80		
JMM 619 7 105 105 JMM 60 655 Alendronate 05 32 667 67 Alendronate 05 32 1 63 100-1500 400-1500 05 33 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		The Lancet	36	652		Alendronate	OS	1022	71	25.50	0.79		0.57
MM 60 653 Alendronate 05 329 667 67 7 8 33 1 657 7 8 33 1 657 7 8 33 1 100-1500 400-1200 2 1 43 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1<	32]			619		Placebo	OS	1005	71	25.60	0.79		0.56
667 677 Alendronate 63 333 180ne Min Res 36 1000-1500 400-1200 Zolectonate 1 1 Bone Min Res 36 1000-1500 400-1200 Zolectonate 1 617 1 Bone Min Res 36 1000-1500 400-1200 Zolectonate 1 617 1 Bone Min Res 36 1000-1500 400-1200 Zolectonate 1 617 1 Bone Min Res 36 1000-1500 400-1200 Zolectonate 1 617 1 Bone Min Res 36 1000-1500 400-1200 Corectonate 0 9 1 Bone Min Res 10 881 Alendronate 0 9 9 1 Bone Min Res 60 500 400 Braceboon 05 9 9 1 Bone Min Res 60 500 400 Braceboon 05 9 9 1 Bone Min Res 56 500 9 9 9 9 9 <	t al. 2006	JAMA	60	655		Alendronate	OS	329	73	25.70	0.90	0.73	0.62
635 635 637 637 637 637 637 637 637 637 637 637 637 637 636 636 <td>33]</td> <td></td> <td></td> <td>667</td> <td></td> <td>Alendronate</td> <td>OS</td> <td>333</td> <td>73</td> <td>25.90</td> <td>0.89</td> <td>0.73</td> <td>0.61</td>	33]			667		Alendronate	OS	333	73	25.90	0.89	0.73	0.61
J Bone Min Res 36 1000-1500 400-1200 Zoledronate IV 616 J Bone Min Res 36 1000-1500 400-1200 Zoledronate IV 617 J Bone Min Res 36 1000-1500 400-1200 Zoledronate IV 617 J Bone Min Res 36 1000-1500 400-1200 Zoledronate IV 617 J Uln Endocrinol 24 813 Alendronate 02 86 J Uln Endocrinol 24 813 Alendronate 05 86 J Clin Endocrinol 12 Alendronate 05 86 93 Osteoporos Int 12 Alendronate 05 93 93 J Bone Min Res 60 500 400 Bindronate 05 93 J Bone Min Res 36 500 93 93 93 93 J Bone Min Res 36 500 93 93 93 93 J Bone Min Res 36 500 <td< td=""><td></td><td></td><td></td><td>635</td><td></td><td>Placebo</td><td>OS</td><td>437</td><td>74</td><td>25.80</td><td>0.90</td><td>0.72</td><td>0.61</td></td<>				635		Placebo	OS	437	74	25.80	0.90	0.72	0.61
		one Min Res	36	1000-1500	400-1200	Zoledronate	\geq	616	76	25.30	0.81	69.0	0.56
J Bone Min Res 36 100-1500 400-1200 Zoledronate IV 95 J Cin Endocrinol 24 813 Placebo 1V 95 J Cin Endocrinol 24 813 Alendronate 05 86 J Cin Endocrinol 24 813 Alendronate 05 86 J Bine Min Res 10 900 Placebo 05 91 U Bone Min Res 10 12 Alendronate 05 852 J Bone Min Res 60 500 400 Plandronate 05 851 J Bone Min Res 60 500 400 Plandronate 05 27 J Bone Min Res 36 500 400 Plandronate 05 27 J Bone Min Res 36 500 400 Plandronate 05 27 J Bone Min Res 36 500 1000 05 27 27 J Bone Min Res 36 500 1000 05 27	34]					Placebo	\geq	617	76	25.60	0.82	0.69	0.57
J Clin Fudocrinol 24 813 Placebo 1 95 Metab 880 Alendronate 05 86 Metab 880 Alendronate 05 89 Sil 81 Alendronate 05 89 Sil 900 81 Alendronate 05 91 Osteoporos Int 12 200 Placebo 05 91 Useewors Int 12 200 200 92 93 Useewors Int 12 200 200 93 93 93 Useewors Int 12 200 200 200 93 93 Useewors Int 13 200 200 200 21 21 Useewors Int 36 500 400 100 21 21 Useewors Int 36 200 21 21 21 Useewors Int 36 200 21 21 21 Useewors Int 36 200 21 21 21 Usteoporos Int 36		one Min Res	36	1000-1500	400-1200	Zoledronate	≥	95	78	24.60		0.69	0.58
J Clin Endocrinol 24 813 Alendronate 05 86 Metab 880 Alendronate 05 89 <td>35]</td> <td></td> <td></td> <td></td> <td></td> <td>Placebo</td> <td>≥</td> <td>95</td> <td>78</td> <td>25.00</td> <td></td> <td>0.71</td> <td>0.58</td>	35]					Placebo	≥	95	78	25.00		0.71	0.58
Metab80Alendronate0589 831 831 81 831 93 93 831 900 90 90 91 93 000 12 900 900 900 93 05 12 12 12 12 12 851 1 12 12 12 12 12 12 1 12 12 12 12 12 12 1 12 12 12 12 12 12 1 12 12 12 12 12 12 1 12 12 12 12 12 12 1 12 12 12 12 12 12 1 12 12 12 12 12 12 1 12 12 120 120 120 127 1 12 120 120 120 121 121 1 120 120 120 120 121 1 120 120 120 120 121 1 120 120 120 120 120 1 120 120 120 120 120 1 120 120 120 120 121 1 120 120 120 120 121 1 120 120 120 120 121 11 120 120 121		in Endocrinol	24	813		Alendronate	OS	86	71				
831 831 90 93 900 900 900 91 91 910 91 91 91 91 91 910 91 91 91 91 91 91 910 91 91 91 91 91 91 91 910 91 91 91 91 91 91 91 91 910 900 900 900 900 900 91 91 91 91 910 91 91 91 91 91 91 91 91 91 910 91	36]	Metab		880		Alendronate	OS	89	20				
900 900 05 91 Osteoporos Int 12 Denosumab 5C 852 J Bone Min Res 60 500 400 Pamidronate 05 851 J Bone Min Res 60 500 400 Pamidronate 05 26 J Bone Min Res 36 500 400 Pamidronate 05 27 J Bone Min Res 36 500 400 Pamidronate 05 27 J Bone Min Res 36 500 400 Ibandronate 05 27 J Bone Min Res 36 500 400 Ibandronate 05 97 Osteoporos Int 36 1000 Stedronate 05 97 Osteoporos Int 36 1000 Risedronate 05 97				831		Alendronate	OS	93	71				
Osteoporos Int 12 Denosumab 5C 852 J Bone Min Res 60 500 400 Pandronate 05 851 J Bone Min Res 60 500 400 Pandronate 05 26 J Bone Min Res 60 500 400 Pandronate 05 26 J Bone Min Res 36 500 400 Ibandronate 05 27 J Bone Min Res 36 500 400 Ibandronate 05 97 J Bone Min Res 36 500 400 Ibandronate 05 97 Osteoporos Int 36 1000 Risedronate 05 97 Osteoporos Int 36 1000 Risedronate 05 97				006		Placebo	OS	91	71				
J Bone Min Res 60 500 400 Risedronate 05 26 J Bone Min Res 60 500 400 Pamidronate 05 26 J Bone Min Res 36 500 400 Ibandronate 05 27 J Bone Min Res 36 500 400 Ibandronate 05 977 O Steoporos Int 36 1000 Risedronate 05 975 O Steoporos Int 36 1000 Risedronate 05 975 O Steoporos Int 36 1000 Risedronate 05 975		teoporos Int	12			Denosumab	SC	852	68				
J Bone Min Res 60 500 400 Pamidronate 05 26 J Bone Min Res 36 500 400 Pamidronate 05 27 J Bone Min Res 36 500 400 Ibandronate 05 27 J Bone Min Res 36 500 400 Ibandronate 05 977 D Bone Min Res 36 500 400 Ibandronate 05 977 O Steoporos Int 36 1000 Risedronate 05 975 O Steoporos Int 36 1000 Risedronate 05 975	4 [37]					Ibandronate	OS	851	67				
J Bone Min Res 60 500 400 Panidronate 05 26 J Bone Min Res 36 500 400 Ibandronate 05 27 J Bone Min Res 36 500 400 Ibandronate 05 977 D Bone Min Res 36 500 400 Ibandronate 05 977 D Bone Min Res 36 1000 Risedronate 05 977 Osteoporos Int 36 1000 Risedronate 05 975						Risedronate	OS						
J Bone Min Res 36 500 400 Ibandronate 05 971 J Bone Min Res 36 500 400 Ibandronate 05 971 Reserved State 100 100 100 100 105 144 Risedronate 05 1000 Risedronate 05 44		one Min Res	60	500	400	Pamidronate	OS	26	99		0.76		0.64
J Bone Min Res 36 500 400 Ibandronate 05 977 Ibandronate 05 97 100 05 977 Ibandronate 05 977 100 05 977 Ibandronate 05 1000 1000 05 975 Ibandronate 36 1000 1000 105 944 Ibandronate/ 05 100 100 100 100	12 [38]					Placebo	OS	27	64		0.74		0.64
Ibandronate OS 977 Placebo OS 975 Osteoporos Int 36 1000 Risedronate OS 44		one Min Res	36	500	400	lbandronate	OS	977	69	26.20			
Osteoporos Int 36 1000 Placebo OS 975 Risedronate 0S Risedronate OS 44	4 [39]					lbandronate	OS	977	69	26.20			
Osteoporos Int 36 1000 Risedronate OS 44 Risedronate/ OS 44						Placebo	OS	975	69	26.20			
Risedronate/ OS 44		teoporos Int	36	1000		Risedronate	OS	44	67	25.50	0.80		0.61
placebo	7 [40]					Risedronate/ placebo	OS	44	68	24.40	0.79		0.61

Page 6 of 15


Author, year	Journal	Follow-up (<i>months</i>)	Calcium daily supplement (<i>mg</i>)	Vit D daily supplement (<i>U</i>)	Treatment	Administration	Samples (<i>n</i>)	Mean age	Mean BMI (<i>kg/m</i> ²)	BMD Spine (g/cm ²)	$\substack{BMD\\(g')\\cm^2}$	BMD Femur neck (g/cm ²)
					Placebo	OS	44	70	25.10	0.75		0.61
Cosman et al.	New England J	12	500-1000	600-800	Romosozumab	SC	3589	71				
2016 [10]	Med				Placebo	SC	3591	71				
		24	500-1000	600-800	Denosumab	SC	3589	71				
					Denosumab	SC	3591	71				
Cummings et al.	JAMA	48	634		Alendronate	OS	2214	68	24.90	0.84		0.59
1998 [41]			638		Placebo	OS	2218	68	25.00	0.84		0.59
Cummings et al.	New England J	36	1000	400-800	Denosumab	SC	3902	72	26.00			
2009 [42]					Placebo	SC	3906	72	26.00			
Delmas et al.	J Clin Endocrinol	48	500	400-600	Raloxifene	OS	2259	99	25.30	0.82		0.62
2002 [43]	Metab				Raloxifene	OS	2277	99	25.20	0.81		0.62
					Placebo	OS	2292	67	25.30	0.81		0.62
Ettinger et al.	JAMA	36	500	400-600	Raloxifene	OS	2259	67				
1999 [7]					Raloxifene	OS	2277					
					Placebo	OS	2292					
Fogelman et al.	J Clir	24	1000		Risedronate	OS	184	65	24.80	0.73		0.63
2000 [44]	Metab				Risedronate	OS	177	65	24.80	0.75		0.64
					Placebo	OS	180	64	25.50	0.74		0.64
Frediani et al.	Clin Drug Invest	24			Alendronate	OS	30	63	20.90	0.81		
1998 [45]					Calcitriol	OS	30	63	21.80	0.81		
					Alendronate/ calcitriol	OS	30	63	21.00	0.80		
					Calcium	OS	30	63	21.20	0.80		
Garg et al. 2015	J So	12			Zoledronate	≥	50					
[46]	Menopause Soc				Teriparatide	SC	50					
Gonnelli et al.	Bone	12	841	400	Zoledronate	≥	30	66	26.10	0.82	0.79	
2014 [47]			870		Ibandronate	≥	30	67	25.70	0.82	0.79	
Greenspan et al.	JAMA	24	807	163	Zoledronate	≥	89	85	28.20	0.93	0.68	0.61
2015 [48]			763	168	Placebo	\geq	92	86	26.90	0.97	0.70	0.62
Grey et al. 2009	J Cli	24	935		Zoledronate	≥	25	62		1.06	0.85	
[49]	Metab		916		Placebo	\geq	25	65		1.03	0.86	

Author, year	Journal	Follow-up (<i>months</i>)	Author, year Journal Follow-up Calcium daily Vit D dail (<i>months</i>) supplement (<i>mg</i>) suppleme	Vit D daily supplement (U)	Treatment	Administration	Samples (<i>n</i>)	Mean age	Mean BMI (<i>kg/m²</i>)	BMD Spine (g/cm²)	BMD Hip (g/ cm ²)	BMD Femur neck (<i>g/cm</i> ²)
Grey et al. 2012	J Clin Endocrinol	12	096		Zoledronate	2	43	64		1.01	0.85	
[50]	Metab		880		Zoledronate	≥	43	99		1.03	0.84	
			850		Zoledronate	≥	43	99		1.05	0.84	
			950		Placebo	≥	43	65		1.03	0.87	
Guanabens et al.	Hepatology	24	1000		lbandronate	OS	14	65	26.60	06.0	0.84	0.79
2013 [51]					Alendronate	OS	19	63	26.60	0.88	0.81	0.77
Harris et al. 1993 [52]	Am J Med	48	500		Phosphate- etidronate	OS	63			0.89		0.67
					Placebo- etidronate	OS	65			0.87		0.69
					Phosphate- placebo	OS	62			0.87		0.67
					Placebo	OS	63			0.86		0.68
Harris et al. 1999	JAMA	36	1000	500	Risedronate	OS	817	69	26.60	0.84		09.0
[53]					Risedronate	OS	821	69	26.60	0.83		0.59
					Placebo	OS	820	68	26.50	0.83		0.60
Hooper et al.	Climacteric	24			Risedronate	10S	128	53		1.08		
2005 [54]					Risedronate	OS	129	53		1.08		
					Placebo	OD	126	53		1.08		
lwamoto et al.	Yonsei Med J	12	800		Alendronate	OS	61	70	21.90	0.62		
2008 [55]					Raloxifene	OS	61	69	21.70	0.65		
Kendler et al.	Osteoporosis Int	12	> 1000	> 800	Romosozumab	SC	16	69				
2019 [56]					Romosozumab	SC	19	68				
					Romosozumab	SC	14					
					Romosozumab	SC	12					
Langdahl et al.	The Lancet	12	500-1000	600-800	Romosozumab	SC	198	72				
2017 [57]					Teriparatide	SC	200	71				
Leder et al. 2015 [58]	The Lancet	48			Teriparatide- denosumab	SC	27	66	25.50	0.82		0.64
					Denosumab- teriparatide	SC	27	65	23.80	0.86		0.64
					Combined- denosumab	SC	23	65	25.90	0.85		0.64

Openetication 10 Constrained 5 7 6 7 6 7 6 7 <th>Author, year</th> <th>Journal</th> <th>Follow-up (<i>months</i>)</th> <th>Calcium daily supplement (<i>mg</i>)</th> <th>Vit D daily supplement (<i>U</i>)</th> <th>Treatment</th> <th>Administration</th> <th>Samples (<i>n</i>)</th> <th>Mean age</th> <th>Mean BMI (<i>kg/m²</i>)</th> <th>BMD Spine (g/cm²)</th> <th>BMD (g/ cm²)</th> <th>BMD Femur neck (g/cm²)</th>	Author, year	Journal	Follow-up (<i>months</i>)	Calcium daily supplement (<i>mg</i>)	Vit D daily supplement (<i>U</i>)	Treatment	Administration	Samples (<i>n</i>)	Mean age	Mean BMI (<i>kg/m²</i>)	BMD Spine (g/cm ²)	BMD (g/ cm²)	BMD Femur neck (g/cm ²)
Weth Filter Denominal EC 33 64 341 63 641 63 641 63 641 631	Leder et al. 2014		24			Teriparatide	SC	31	66	25.50	0.82		0.64
Attraction of the field of the fie	[59]	Metab				Denosumab	SC	33	99	24.10	0.87		0.64
Jenefaction Matria Composition 12 247 247 247 247 Orthop Stage 24 2 292 7 249 7 240 Orthop Stage 12 2 292 7 249 7 249 Orthop Stage 12 2 249 7 249 <td></td> <td></td> <td></td> <td></td> <td></td> <td>Combined</td> <td>SC</td> <td>30</td> <td>99</td> <td>25.40</td> <td>0.86</td> <td></td> <td>0.64</td>						Combined	SC	30	99	25.40	0.86		0.64
Wate Temp Temp <th< td=""><td>Lewiecki et al.</td><td>J Clin Endocrinol</td><td>12</td><td></td><td></td><td>Denosumab</td><td>SC</td><td>3003</td><td>71</td><td>24.70</td><td></td><td></td><td></td></th<>	Lewiecki et al.	J Clin Endocrinol	12			Denosumab	SC	3003	71	24.70			
Othop Sug 24 2 2 2 2 2 3 2 3	2018 [60]	Metab				Denosumab	SC	3042	71	24.70			
JBore Minites 12 2 160 05 2160 05 2160 05	Liang et al. 2017		24			Zoledronate	≥	155	57	21.80	0.63	0.75	
Jêne Min les 12 Pacebo 05 43 64 210 Jêne Min les 12 730 800/fine 05 48 07 2480 07 04 Routin les 30 40 61 49 07 249 07 04 Routin les 40 50 61 72 250 07 07 07 Ne Figuru l 13 10 100 800 61 7 250 07 07 07 Ne Figuru l 13 10 100 800 61 7 25 07 07 07 Ne Figuru l 10	[61]					Placebo	≥	95	57	21.60	0.63	0.75	
JBore Min Rs 12 Ration Rs 05 48 64 248 07 249 07 03 750 730 400 61 05 42 520 03 03 750 610 610 610 610 61 62 530 03 03 750 60 610 610 61 67 520 03 03 750 60 610 61 62 530 03 03 750 610 610 61 62 62 03 03 8 60 62 62 63 63 63 63 8 60 62 63 63 63 63 63 9 10 10 80 63 63 63 63 9 10 10 10 10 10 10 10 10 10 9 <td< td=""><td></td><td></td><td></td><td></td><td></td><td>Placebo</td><td>OS</td><td>355</td><td>64</td><td>24.10</td><td></td><td></td><td></td></td<>						Placebo	OS	355	64	24.10			
Allocitiene Cloc 47 620 0.01	Lufkin et al. 1998		12			Raloxifene	OS	48	67	24.80	0.75	0.64	
730 400 Calcurviti 6 530 617 60 Cin Rheumatol 48 500 50 72 730 07 07 07 New England 10 100 800 610mwit 07 520 07 07 07 07 New England 12 1000 800 800 800 800 07 07 07 07 07 New England 12 100 800 800 800 800 800 07 07 07 New England 12 100 800 800 87 97 97 97 Chantower 24 67 72 67 67 67 97 97 New England 24 67 72 67 67 67 67 67 67 67 67 67 67 68 66 67 68 68 66 67 67	[62]					Raloxifene	OS	47	67	26.20	0.81	69:0	
Clin Rheumated 48 500 Eticitomate 05 32 27.60 057 New England J 12 100 800 Romoscumale 5 44 67 56 057 New England J 12 100 800 Romoscumale 5 44 67 56 057 New England J 12 100 800 Romoscumale 55 67 67 67 55 55 55 55 55 55 55 55 55 55 55 55 55 55 55 55 55 55 56 55				750	400	Calcium/vit D	OS	48	68	25.30	0.77	0.67	
New England 12 100 800 Raturwit 5 2 2890 057 New England 12 100 800 Romoszumal 5 44 67 7 549 057 New England 1 Romoszumal 5 44 67 67 67 67 Romoszumal 5 67 67 67 67 67 67 67 Romoszumal 5 67 67 67 67 67 67 67 67 Romoszumal 5 67 67 67 67 67 67 67 Romoszumal 5 67 68 68 68 68 68 68 68 68 68 68 68 68	Lyritis et al. 1997		48	500		Etidronate	OS	39	72	27.60	0.57		0.42
New England 12 100 800 Remosszumab 5C 44 67 Remosszumab 7 8mosszumab 7 49 67 7 Remosszumab 7 8mosszumab 7 67 67 67 Remosszumab 7 7 67 67 67 67 Remosszumab 7 7 7 7 7 7 Remosszumab 7 7 7 7 7 7 Remosszumab 7 7 7 7 7 7 7 Remosszumab 7 7 7 7 7 7 7 Statistic 2 7 7 7	[03]					Calcium/vit D	OS	35	72	26.80	0.57		0.43
Med Emosoration SC 46 67 Remosoration SC 99 67 Remosoration SC 99 67 Remosoration SC 97 67 Remosoration SC 59 67 Remosoration SC 59 67 Remosoration SC 57 67 Remosoration SC 57 67 Remosoration SC 57 67 Remosoration SC 67 67 Remosoration SC 164 67 Remosoration SC 124 67 Remosoration SC	McClung et al.		12	1000	800	Romosozumab	SC	44	67				
Remoszumal 5C 49 67 Remoszumal 5C 52 67 Remoszumal 5C 53 67 Remoszumal 5C 53 67 Remoszumal 5C 74 67 Remoszumal 5C 74 67 Remoszumal 5C 46 67 Remoszumal 7C 74 75 Remoszumal 7C 76 76 Remoszumal 7C 76 76 Remoszumal 7C 76 73 Remoszumal 7C 77 75	2014 [64]					Romosozumab	SC	46	67				
Remoszundi Remoszundi Sectorati Alendronate SC 52 67 Remoszundi Remoszundi Alendronate SC 53 67 Alendronate SC 73 67 Alendronate SC 74 67 Alendronate SC 47 67 Alendronate SC 47 67 Alendronate SC 47 67 Alendronate SC 47 67 Alendronate SC 181 67 Alendronate <td></td> <td></td> <td></td> <td></td> <td></td> <td>Romosozumab</td> <td>SC</td> <td>49</td> <td>67</td> <td></td> <td></td> <td></td> <td></td>						Romosozumab	SC	49	67				
Remoszumal SC 53 67 Alendronate OS 47 67 Alendronate SC 46 67 Alendronate SC 46 67 Döstetőynecol 24 67 67 Obstetőynecol 24 67 67 Jbone Min Res 10 40-800 Zoledronate 17 67 036 Jbone Min Res 12 1000 800 Zoledronate 17 67 036 Jbone Min Res 12 1000 800 Denosumal 57 17 05 036 Vew England J 36 1000 800 Denosumal 57 17 16 16 New England J 36 1000 800 2000 17 16 16 16 Med 13 1000 800 17 16 16 16 16 16 16 16 16 16 16 16 16 <td></td> <td></td> <td></td> <td></td> <td></td> <td>Romosozumab</td> <td>SC</td> <td>52</td> <td>67</td> <td></td> <td></td> <td></td> <td></td>						Romosozumab	SC	52	67				
Alendroate CS 47 67 Terparatide SC 47 67 Terparatide SC 47 67 Disterbyneeol 24 500-1200 400-800 20 echonate 17 67 Disterbyneeol 24 500-1200 400-800 20 echonate 17 67 036 J Bone Min Res 12 1000 800 20 echonate 17 67 2730 036 J Bone Min Res 12 1000 800 Denosumab 5C 127 036 036 New England J 36 1000 800 Denosumab 5C 127 036 036 New England J 36 1000 800 Strontum 05 127 045 136 New England J 36 1000 800 137 67 036 046 New England J 36 1000 137 67 073 045 045 045 045						Romosozumab	SC	53	67				
						Alendronate	OS	47	67				
District/orecul 24 500-1200 400-800 Electron 67 67 Obstret/Gynecul 24 500-1200 400-800 Zoledronate 1V 181 60 2650 036 J Bone Min Res 12 100 800 Zoledronate 1V 154 60 2730 036 J Bone Min Res 12 100 800 Denosumab 5C 127 67 730 036 New England J 36 1000 800 Denosumab 5C 131 67 7 7 New England J 36 1000 800 Strontum 05 719 67 7 7 New England J 36 1000 400-800 Strontum 05 719 67 7 7 7 7 Oteoporots Int 12 100 400-800 Strontum 05 2620 073 059						Teriparatide	SC	46	67				
Obstetcynecol 24 500-1200 400-800 Zoledronate V 181 60 26.50 086 Zoledronate V 214 V 154 60 27.30 086 Zoledronate V 154 60 27.30 086 Zoledronate V 188 61 27.20 086 J Bone Min Res 12 1000 800 Denosumab 5C 127 67 729 086 New England J 36 1000 800 Denosumab 5C 131 67 720 086 New England J 36 1000 400-800 Strontum 05 719 67 73 67 73 74 Med Med 1 1 67 719 719 719 75 75 Now England J 12 1000 400-800 Strontum 05 723 69 739 708 708 708 708						Placebo	SC	47	67				
JBone Min Res 12 1000 800 Coledonate- placebo V 154 60 2730 086 JBone Min Res 12 1000 800 Denosumab 5C 127 67 0.86 New England J 36 100 800 Denosumab 5C 127 67 79 0.86 New England J 36 1000 400-800 Strontium 05 719 67 719 67 713 059 050 Osteoporos Int 12 1000 400-800 Strontium 05 723 69 730 059 058 Osteoporos Int 12 1000 400-800 Strontium 05 221 72 058	McClung et al.		24	500-1200	400-800	Zoledronate	\geq	181	60	26.50	0.86		0.69
J Bore Min Res 12 100 800 Placebo K 188 61 27.20 0.86 J Bore Min Res 12 100 800 Denosumab SC 127 67 0.86 New England J 36 1000 400-800 Strontium OS 719 67 0.73 0.69 New England J 36 1000 400-800 Strontium OS 719 69 26.20 0.73 0.69 Osteopors Int 12 100 400-800 Strontium OS 723 69 26.20 0.73 0.68	2009 [65]					Zoledronate- placebo	≥	154	60	27.30	0.86		0.69
J Bone Min Res 12 1000 800 Denosumab 5C 127 67 New England J 36 1000 400-800 Strontium 05 131 67 New England J 36 1000 400-800 Strontium 05 719 69 26.20 0.73 0.69 Osteoporos Int 12 1000 400-800 Strontium 05 723 69 26.20 0.73 0.69 Osteoporos Int 12 1000 400-800 Strontium 05 221 72 0.85						Placebo	≥	188	61	27.20	0.86		0.69
New England J 36 100 400-800 Strontium OS 719 67 733 059 059 059 059 059 059 059 059 059 059 059 059 059 059 059 059 059 059 058 059 058	McClung et al.	J Bone Min Res	12	1000	800	Denosumab	SC	127	67				
New England J 36 100 400-800 Strontium OS 719 69 26.20 0.73 0.69 Med Placebo OS 723 69 26.20 0.72 0.68 Osteoporos Int 12 100 400-800 Strontium OS 221 72 0.68	2018 [66]					Placebo	SC	131	67				
Discreporos Int 12 100 400-800 Strontium 0S 723 69 26.20 0.72 0.68 Intersection 00 400-800 Strontium 0S 221 72 0.85 Intersection 0S Strontium 0S 0S 0.85 0.85	Meunier et al. 2004 [67]	New England J Med	36	1000	400-800	Strontium ranelate	OS	719	69	26.20	0.73		0.59
Osteoporos Int 12 1000 400-800 Strontium OS 221 72 0.85 ranelate						Placebo	OS	723	69	26.20	0.72		0.59
	Meunier et al. 2009 [68]	Osteoporos Int	12	1000	400-800	Strontium ranelate	OS	221	72		0.85		0.66

Author, year	Journal	Follow-up (<i>months</i>)	Calcium daily supplement (<i>mg</i>)	Vit D daily supplement (UI)	Treatment	Administration Samples (n)	Samples (<i>n</i>)	Mean age	Mean BMI (<i>kg/m²</i>)	BMD Spine (<i>g/cm</i> ²)	BMD (g')	BMD Femur neck (<i>g/cm</i> ²)
					Strontium ranelate	OS	434	72		0.72		0.58
					Placebo	OS	225	72		0.86		0.64
Miller et al. 2016	J Clir	12	1000	800	Denosumab	SC	321	69	24.30			
[69]	Metab				Zoledronate	\geq	322	70	24.30			
Miyauchi et al.	Arch Osteoporos	36	500-1000	600-800	Denosumab	SC	247	71	21.10			
2019 [68]					Denosumab	SC	245	20	21.40			
Montessori et al.	Osteoporos Int	36			Etidronate	OS	40	62		0.68	0.67	0.60
1997 [70]					Calcium	OS	40	63		0.67	0.69	0.61
Morii et al. 2003	Osteoporos Int	13			Raloxifene	OS	06	65	21.50	0.66		
[17]					Raloxifene	OS	93	65	21.90	0.67		
					Placebo	OS	97	64	22.00	0.64		
Mortensen et al.	L Cli	36	937		Risedronate	OS	37	52		0.93		0.74
1998 [72]	Metab		1057		Risedronate	OS	38	51		0.93		0.71
			936		Placebo	OS	36	51		0.96		0.74
Neer et al. 2001	New	24	1000	400-1200	Teriparatide	SC	444	69		0.82	0.70	0.64
[73]	Med				Teriparatide	SC	434	20		0.82	0.70	0.64
					Placebo	SC	448	69		0.82	0.71	0.64
Paggiosi et al.	Osteoporos Int	24	1200	800	Alendronate	OS	57	68	25.90	0.79	0.75	0.64
2014 [74]					Ibandronate	OS	58	67	26.40	0.80	0.78	0.64
					Risedronate	OS	57	67	26.80	0.81	0.80	0.67
					Control		226	38	25.10	1.,07	0.97	0.86
Papapoulos et al.	J Bone Min Res	24			Denosumab	SC	2343	75				
2012 [75]					Denosumab	SC	2207	75				
Papapoulos et al.	Osteoporos Int	60	> 1000	> 400	Denosumab	SC	2343	62				
2015 [76]					Denosumab	SC	2207	79				
Popp e t al. 2013	Maturitas	36	1000-1500	400-1200	Zoledronate	\geq	55	77	24.60	0.77	0.67	0.56
[77]					Placebo	≥	55	77	24.40	0.77	0.67	0.55
Recknor et al.	ObstetGynecol	12	500	800	Denosumab	SC	417	67	25.50			
2013 [26]					Ibandronate	OS	416	99	25.10			
Reginster et al.	Osteoporos Int	36	500-1000	400-800	Strontium	OS	879	79	25.90	0.93	0.73	0.61

Author, year	Journal	Follow-up (<i>months</i>)	Calcium daily supplement (<i>mg</i>)	Vit D daily supplement (<i>U</i>)	Treatment	Administration Samples (n)	Samples (<i>n</i>)	Mean age	Mean BMI (<i>kg/m²</i>)	BMD Spine (<i>g/cm</i> ²)	BMD (g')	BMD Femur neck (<i>g/cm</i> ²)
2009 [78]					ranelate							
					Control	OS	892	74	25.90	0.77	0.67	0.57
Reginster et al. 2011 [79]	Osteoporos Int	60	500-1000	400-800	Strontium ranelate	OS	233	77	25.80	0.76	0.69	0.58
					Placebo	OS	458	76	25.20			
Roux et al. 2014	Bone	12	≥ 1000	≥ 800	Denosumab	SC	435	68				
[80]					Risedronate	OS	435	68				
Saag et al. 2017	New England J	24			Alendronate	OS	2047	74	25.40			
[11]					Romosozumab- alendronate	SC-OS	2046	74	25.50			
Tsai et al. 2013	The Lancet	12			Teriparatide	SC	31	66	25.50	0.82	0.76	0.64
[81]					Denosumab	SC	33	99	24.10	0.87	0.77	0.64
					Teriparatide/ denosumab	SC	30	66	25.40	0.86	0.76	0.64
Tsai et al. 2019 [82]	The Lancet	15			Teriparatide- denosumab	SC	35	99	23.00	0.83	0.74	0.65
					Teriparatide- denosumab	SC	34	67	22.80	0.79	0.74	0.62
Tucci et al. 1996	Am J Med	36	500		Alendronate	OS	98	67	23.90			
[83]					Alendronate	OS	94	64	23.30			
					Alendronate	OS	94	49	23.70			
					Placebo	OS	192	49	23.80			
Jiang et al. 2003	J Bone Min Res	19	1000	400-1200	Teriparatide	SC	18	68		0.77		0.61
[84]					Teriparatide	SC	14	68		0.84		0.62
					Placebo	SC	19	68		0.86		0.65



pronounced beneficial effects on BMD. This was also confirmed previously, with denosumab more effective than ibandronate and alendronate [24–28].

Limitations of this network meta-analysis include the focus on the effects of osteoporosis treatments on spinal and hip BMD without an assessment of fracture risk reduction, adverse events or costs. The investigation of adverse effects seems to be particularly important, since adverse effects can affect adherence to treatment. Also, we only included studies which evaluated the effects of anti-osteoporosis medications for postmenopausal osteoporosis, but not for age-related, senile, or secondary osteoporosis. Further studies are necessary to examine these aspects. The minimum follow-up for a study to be included in the present network meta-analysis was 1 year. However, osteoporosis requires long-term treatment to produce clinically relevant benefits. This is especially important when certain medications, such as denosumab, have to be discontinued, and thereby lead to a potential increase in fracture risk. Another potential limitation is related to the limited variety of drugs included for analysis. Given the lack of studies in the literature, some commonly used medications, such as abaloparatide and romosozumab, were not included in the analyses. In light of these limitations, data from the present Bayesian network meta-analysis must be interpreted with caution.

Strengths of our study are the comprehensive literature search of multiple databases in multiple languages, which led to the inclusion of 64 evidence levels I and II RCTs with a total of 82,732 interventions. We also performed a rigorous review process, which was performed by two independent reviewers. Finally, we summarised and analysed the latest evidence of anti-osteoporosis medications on BMD in postmenopausal women from RCTs with the highest levels of evidence, which to our knowledge has not been performed before.

Conclusion

The present network meta-analysis shows that denosumab followed by pamidronate and zoledronate is associated with higher spine BMD in selected women with postmenopausal osteoporosis. Denosumab followed by alendronate and ibandronate had the highest influence on hip and femoral BMD. Future studies should evaluate the effects of anti-osteoporosis drugs on the overall fracture risk and on other types of osteoporosis.

Abbreviations

BMD: Bone mineral density; RANK-ligand: Receptor activator of nuclear factor-kappa B ligand; SERM: Selective oestrogen receptor modulators; BP: Bisphosphonates; PTHR1: Teriparatide; RCTs: Randomised controlled trials; SMD: Standardised mean difference; ANOVA: Analysis of variance; STD: Standardised mean difference; SE: Standard error; CI: Confidence interval; PrI: Percentile interval; BMI: Body mass index

Acknowledgements

None

Authors' contributions

FM: literature search, data extraction, methodological quality assessment, statistical analyses, writing; NM: supervision, revision, final approval; GC: literature search, data extraction, methodological quality assessment; MB: writing; JE, MOB; MT: supervision.

Funding

No external source of funding was used. Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials

This study does not contain any third material.

Declarations

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

All the authors approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074 Aachen, Germany. ²Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081 Baronissi, Salerno, Italy. ³Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Mile End Hospital, 275 Bancroft Road, London E1 4DG, England. ⁴School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Thornburrow Drive, Stoke on Trent, England. ⁵Department of Orthopaedics and Trauma Surgery, University Hospital Mannheim, Medical Faculty of the University Heidelberg, Mannheim, Germany.

Received: 27 April 2021 Accepted: 16 August 2021 Published online: 27 August 2021

References

- Modi A, Sajjan S, Gandhi S. Challenges in implementing and maintaining osteoporosis therapy. Int J Women's Health. 2014;6:759–69.
- Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019; 393(10169):364–76. https://doi.org/10.1016/S0140-6736(18)32112-3.

- Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–16. https://doi.org/10.1056/ NEJMra067395.
- Anastasilakis AD, Polyzos SA, Makras P. Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018;179(1):R31–45. https://doi.org/10.1530/ EJE-18-0056.
- van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999;264(1):108–11. https://doi.org/10.1006/bbrc.1999.1499.
- Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006;103(20):7829–34. https://doi.org/10.1073/pnas.0601643103.
- Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45. https://doi.org/10.1001/ jama.282.7.637.
- Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res. 2007;22(8):1173–80. https://doi.org/10.1359/jbmr.070413.
- Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int. 2016;99(5):489–99. https://doi.org/10.1007/ s00223-016-0171-1.
- Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948.
- Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27. https://doi.org/10.1056/ NEJMoa1708322.
- Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84. https://doi.org/10. 7326/M14-2385.
- Howick J Cl, Glasziou P, Greenhalgh T, Carl Heneghan, Liberati A, Moschetti I, Phillips B, Thornton H, Goddard O, Hodgkinson M. 2011. The 2011 Oxford CEBM levels of evidence. Oxford Centre for Evidence-Based Medicine Available at https://www.cebmnet/indexaspx?o=5653.
- Reginster J, Bianic F, Campbell R, et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465–73. https://doi.org/10.1007/s00198-019-04947-2.
- Tan X, Wen F, Yang W, Xie JY, Ding LL, Mo YX. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). Menopause. 2019; 26(8):929–39. https://doi.org/10.1097/GME.00000000001321.
- Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, et al. Network metaanalysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem. 2016;40(3-4):781–95. https://doi.org/10.11 59/000453138.
- Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, et al. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone. 2020;130:115081. https://doi.org/10.1016/j.bone.2019.115081.
- Chandran T, Venkatachalam I. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singap Med J. 2019;60(7):364–78. https:// doi.org/10.11622/smedj.2019028.
- Sornay-Rendu E, Boutroy S, Munoz F, Bouxsein ML. Cortical and trabecular architecture are altered in postmenopausal women with fractures. Osteoporos Int. 2009;20(8):1291–7. https://doi.org/10.1007/s001 98-009-1008-9.

- Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015;11(3):461–70. https:// doi.org/10.1517/17425255.2015.1000860.
- Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23. https:// doi.org/10.1016/S2213-8587(17)30138-9.
- Kendler DL, Macarios D, Lillestol MJ, Moffett A, Satram-Hoang S, Huang J, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause. 2014;21(1):25–32. https://doi.org/1 0.1097/GME.0b013e31828f5e5d.
- Palacios S, Agodoa I, Bonnick S, van den Bergh JP, Ferreira I, Ho PR, et al. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. J Clin Endocrinol Metab. 2015;100(3):E487–92. https://doi.org/10.1210/jc.2014-3594.
- Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009; 24(1):153–61. https://doi.org/10.1359/jbmr.0809010.
- Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81. https://doi.org/10.1359/jbmr.090716.
- Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291–9. https://doi.org/10.1097/AOG.0b013 e318291718c.
- Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886– 94. https://doi.org/10.1002/jbmr.81.
- Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173–9. https://doi.org/10.101 6/j.bone.2013.11.016.
- Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int. 2015;26(10):2521–7. https://doi.org/10.1007/ s00198-015-3174-2.
- Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22. https://doi.org/10.1056/NEJMoa067312.
- Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87(10):4528–35. https://doi.org/10.1210/jc.2002-020334.
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–41.
- Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38. https://doi.org/10.1001/jama.296.24.2927.
- 34. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243–54. https://doi.org/10.1002/jbmr.1494.
- Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934–44. https://doi.org/10.1002/jbmr.2442.
- Bone HG, Downs RW Jr, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab. 1997;82(1):265–74. https://doi.org/10.1210/jcem.82.1.3682.

- 37. Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int. 2014;25(7):1953–61. https://doi.org/10.1007/s00198-014-2692-7.
- Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PHLM, Hamdy NAT, Landman JO, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2year open extension. J Bone Miner Res. 2002;17(6):1057–64. https://doi.org/1 0.1359/jbmr.2002.17.6.1057.
- Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–9. https://doi.org/10.1359/ JBMR.040325.
- Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int. 1997;7(5):488–95. https://doi. org/10.1007/PL00004152.
- Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–82. https://doi.org/10.1001/ja ma.280.24.2077.
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. https://doi.org/10.1056/NEJMoa0809493.
- Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87(8):3609–17. https://doi.org/10.1210/jcem.87.8.8750.
- Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000;85:1895–900.
- 45. Frediani B, Allegri A, B S, et al. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis two years of continuous treatment. Clin Drug Investig. 1998; 15(3):235–44. https://doi.org/10.2165/00044011-199815030-00008.
- Jain MAA, Garg R. A comparative study of use of zoledronic acid and teriparatide in postmenopausal osteoporosis. J South Asian Feder Menopause Soc. 2015;3:6–8.
- Gonnelli S, Caffarelli C, Tanzilli L, Pondrelli C, Lucani B, Franci BM, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone. 2014;61:27–32. https://doi.org/10.1016/j.bone.2013.12.017.
- Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med. 2015;175(6):913–21. https://doi. org/10.1001/jamainternmed.2015.0747.
- Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009;94(2):538–44. https://doi.org/10.1210/jc.2008-2241.
- Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(1):286–92. https://doi.org/1 0.1210/jc.2011-2081.
- Guanabens N, Monegal A, Cerda D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58(6):2070–8. https://doi. org/10.1002/hep.26466.
- Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, et al. Fouryear study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95(6):557–67. https://doi.org/10.1016/0002-9343(93)90350-X.
- Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–52.

- Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric. 2005;8(3):251– 62. https://doi.org/10.1080/13697130500118126.
- Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J. 2008;49(1):119–28. https://doi.org/10.3349/ymj.2008.49.1.119.
- Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019;30(12): 2437–48. https://doi.org/10.1007/s00198-019-05146-9.
- Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390(10102):1585–94. https://doi.org/10.1016/S0140-6736(17)31613-6.
- Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147–55. https://doi.org/10.1016/S0140-6736(15)61120-5.
- Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SAM, Zhu Y, Foley K, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694–700. https://doi. org/10.1210/jc.2013-4440.
- Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019;34(3):419–28. https://doi.org/10.1002/jbmr.3622.
- Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, et al. Intravenous zoledronic acid 5 mg on bone turnover markers and bone mineral density in East China subjects with newly diagnosed osteoporosis: a 24-month clinical study. Orthop Surg. 2017;9(1):103–9. https://doi.org/10.1111/os.12307.
- 62. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res. 1998;13(11):1747–54. https://doi.org/10.1359/jbmr.1998.13.11.1747.
- Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clin Rheumatol. 1997;16(4):354–60. https:// doi.org/10.1007/BF02242451.
- 64. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. https://doi.org/10.1056/NEJMoa1305224.
- McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol. 2009;114(5):999–1007. https://doi.org/10.1097/AOG. 0b013e3181bdce0a.
- McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397–406. https://doi.org/10.1002/jbmr.3452.
- Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459–68. https://doi. org/10.1056/NEJMoa022436.
- Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(10): 1663–73. https://doi.org/10.1007/s00198-008-0825-6.
- Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163–70. https://doi.org/10.1210/jc.2016-1801.
- Montessori ML, Scheele WH, Netelenbos JC, et al. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos Int. 1997;7(1):52– 8. https://doi.org/10.1007/BF01623461.

- Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int. 2003; 14(10):793–800. https://doi.org/10.1007/s00198-003-1424-1.
- Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83(2): 396–402. https://doi.org/10.1210/jcem.83.2.4586.
- Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19): 1434–41. https://doi.org/10.1056/NEJM200105103441904.
- Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2014;25(12): 2729–41. https://doi.org/10.1007/s00198-014-2817-z.
- Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701. https://doi.org/10.1002/jbmr.1479.
- Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773–83. https://doi.org/10.1007/s00198-015-3234-7.
- Popp AW, Buffat H, Cavelti A, Windolf M, Perrelet R, Senn C, et al. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON. Maturitas. 2014;77(3):287–93. https:// doi.org/10.1016/j.maturitas.2013.12.013.
- Reginster JY, Bruyere O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone. 2009;45(6):1059–64. https://doi.org/10.1016/j.bone.2009.08.004.
- Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 2012; 23(3):1115–22. https://doi.org/10.1007/s00198-011-1847-z.
- Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48–54. https://doi.org/1 0.1016/j.bone.2013.10.006.
- Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–6. https://doi.org/10.1016/S0140-6736(13)60856-9.
- Tsai JN, Lee H, David NL, Eastell R, Leder BZ. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019;7(10): 767–75. https://doi.org/10.1016/S2213-8587(19)30255-4.
- Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med. 1996;101(5):488–501. https://doi.org/10.1016/ S0002-9343(96)00282-3.
- Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18(11):1932–41. https://doi.org/10.1359/jbmr.2003.18.11.1932.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.